Common Contracts

EXTENSION AND BRIDGE FUNDING AGREEMENT

Extension and Bridge Funding Agreement • March 12th, 2010 • Cordex Pharma, Inc. • Biological products, (no disgnostic substances)

• Contract Type
  Extension and Bridge Funding Agreement
• Filed
  March 12th, 2010
• Company
  Cordex Pharma, Inc.
• Industry
  Biological products, (no disgnostic substances)

THIS EXTENSION AND BRIDGE FUNDING AGREEMENT (this “Agreement”) is entered into on March 4, 2010 by and among Cordex Pharma, Inc., a Nevada corporation, f/k/a Duska Therapeutics, Inc., a Nevada corporation (the “Company”), and the Company’s subsidiary Duska Scientific Co., a Delaware corporation (such subsidiary, the “Guarantor” and together with the Company, the “Debtors”), on the one hand, and Platinum-Montaur Life Sciences LLC (“PMLS”), Platinum Long Term Growth VI, LLC (“PLTG”), Firebird Global Master Fund Ltd. (“FGMF”), Firebird Global Master Fund II Ltd. (“FGMF II”), ICON Capital Partners, LP (“ICP”), Philip and Debra Sobol Trust (“PDST”) and BridgePointe Master Fund Ltd. (“BridgePointe,” together with PMLS, PLTG, FGMF, FGMF II and PDST, each individually referred to as a “Holder” and collectively as the “Holders”), on the other hand. Capitalized terms not defined in this Agreement shall have the meanings ascribed to such terms in each of the Securities Purchase Agreement (as defi

EXTENSION AND BRIDGE FUNDING AGREEMENT

Extension and Bridge Funding Agreement • February 24th, 2010 • Cordex Pharma, Inc. • Biological products, (no disgnostic substances)

• Contract Type
  Extension and Bridge Funding Agreement
• Filed
  February 24th, 2010
• Company
  Cordex Pharma, Inc.
• Industry
  Biological products, (no disgnostic substances)

THIS EXTENSION AND BRIDGE FUNDING AGREEMENT (this “Agreement”) is entered into on February 17, 2010 by and among Cordex Pharma, Inc., a Nevada corporation, f/k/a Duska Therapeutics, Inc., a Nevada corporation (the “Company”), and the Company’s subsidiary Duska Scientific Co., a Delaware corporation (such subsidiary, the “Guarantor” and together with the Company, the “Debtors”), on the one hand, and Platinum-Montaur Life Sciences LLC (“PMLS”), Platinum Long Term Growth VI, LLC (“PLTG”), Firebird Global Master Fund Ltd. (“FGMF”), Firebird Global Master Fund II Ltd. (“FGMF II”), ICON Capital Partners, LP (“ICP”), Philip and Debra Sobol Trust (“PDST”) and BridgePointe Master Fund Ltd. (“BridgePointe,” together with PMLS, PLTG, FGMF, FGMF II and PDST, each individually referred to as a “Holder” and collectively as the “Holders”), on the other hand. Capitalized terms not defined in this Agreement shall have the meanings ascribed to such terms in each of the Securities Purchase Agreement (as